chartexchange

New clinical data on lecanemab to be presented at CTAD conference 2026

Cision | Oct 30, 2026 3:00 AM EDT

Stockholm, Sweden, October 30, 2026 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, November 16-19, 2026. The presentations will include five-year data from the Clarity AD study, as well as findings from the real-world LEADER study in diverse US clinical settings. In addition, BioArctic will present a poster on the binding profile of lecanemab.
New real-world LEADER data demonstrate how lecanemab is being used in clinical

Read original article